摘要
目的:观察豁痰化瘀方治疗冠心病心绞痛合并代谢综合征的临床疗效。方法:将80例冠心病心绞痛合并代谢综合征患者根据随机数字表法分成治疗组44例和对照组36例。对照组采用单纯西药治疗,治疗组在对照组治疗基础上加用豁痰化瘀方治疗,两组患者均以30 d为1个疗程,共治疗1个疗程。观察两组患者治疗后西雅图心绞痛量表评分、心电图、心绞痛临床疗效,并检测血糖、血脂等生化指标的变化。结果:两组患者治疗后心绞痛疗效比较,对照组有效率为72.2%,治疗组有效率为88.6%,差异有统计学意义(P<0.05);两组患者心电图疗效比较,对照组有效率为63.9%,治疗组有效率为90.9%,差异有统计学意义(P<0.05);两组患者血脂水平比较,治疗组治疗前后血脂各项指标比较,差异有统计学意义(P<0.01),对照组治疗前后血脂各项指标比较,差异无统计学意义(P>0.05),治疗后两组比较,差异有统计学意义(P<0.05);空腹血糖、餐后2 h血糖、空腹胰岛素、稳态模型的胰岛素抵抗指数与治疗前比较均有明显改善,差异有统计学意义(P<0.01),治疗后两组患者空腹胰岛素、稳态模型的胰岛素抵抗指数比较,差异有统计学意义(P<0.05);两组患者治疗前后西雅图心绞痛量表评分比较,差异有统计学意义(P<0.05)。结论:豁痰化瘀方可显著减轻治疗冠心病合并代谢综合征患者心绞痛症状,临床疗效显著。
Objective： To observe the clinical efficacy of Huotanhuayu prescription in the treatment of coronary heart disease-angina pectoris combined metabolic syndrome. Methods： 80 cases of patients according to the table in randomly divided into the treatment group（ 44 cases） and control group（ 36 cases）. The control group was treated with western medicine,and the treatment group based on the control group the use of Huotanhuayu prescription,two groups of patients were 30 days as a course of treatment,a total of one course of treatment. Observed the treatment of the two groups of patients with angina pectoris of coronary heart disease complicated with metabolic syndrome after Seattle Angina scale score,ECG,clinical curative effect of angina pectoris,and blood glucose,lipid and biochemical changes. Results： Comparison of the clinical efficacy of ECG and stenocardia between treatment group and control group showed that the former was better than the latter and the difference was significant（ P〈0. 05）; the Blood lipidindicator of the treatment group varies noticeably after treatment and the difference was of statistical significance（ P〈0. 01）,while the blood lipid indicator of the control group varies insignificantly（ P〈0. 05）; comparison of blood lipid indicator between the two groups was of statistical significance（ P〈0. 05）. The indicators of blood lipid,fasting blood glucose,blood glucose 2 hours after dieting,fasting insulin and HOMA-IR after treatment and those before treatment vary noticeably,and the differences were of statistical value（ P〈0. 01）; the differences of fasting insulin and HOMA-IR between the two groups after treatment were of statistical significance（ P〈0. 05）. Conclusion： Huotanhuayu prescription is an effective prescription in the treatment of coronary heart disease-angina pectoris combined metabolic syndrome.
出处
《中医学报》
CAS
2016年第6期865-868,共4页
Acta Chinese Medicine
基金
2016年度河南省高校科技创新团队支持计划(16IRTSTHN023)
关键词
冠心病心绞痛合并代谢综合征
豁痰化瘀方
血糖
血脂
胰岛素抵抗指数
coronary heart disease-angina pectoris combined metabolic syndrome
Huotanhuayu prescription
blood glucose
blood lipid
insulin resistance index
